Key Details
Price
$342.41Annual ROE
-6.94%Beta
0.68Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Oct 30, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
Mar 08, 2002Analyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
BIO's strong results from the ddPCR platform and the growth in clinical diagnostics are promising for investors.
MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has announced that it won another case against Miltenyi Biotec B.V. & Co. KG. The claim states that Miltenyi Biotec created antibodies using information gained from reverse engineering Bio-Techne's exclusive R&D Systems branded NKG2C/CD159c antibodies.
BIO-key, a company from New Jersey that specializes in biometric and cyber security solutions, will be presenting and taking part in DealFlow's Atlantic City Microcap Conference on January 29 and 30.
MINNEAPOLIS, Dec. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has announced that Kim Kelderman, the President and CEO, will speak at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 10:30 a.m.
MINNEAPOLIS, Dec. 19, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a leader in automated platforms for biotherapeutic characterization, has announced a partnership with Waters Corporation to enhance biotherapeutic development processes. The two companies will merge their strengths in charge separation with Bio-Techne's MauriceFlex™ System and Waters' BioAccord™ LC-MS System to create innovative solutions that streamline workflows, increase accuracy, and speed up development.
HOLMDEL, N.J., Dec. 09, 2024 (GLOBE NEWSWIRE) -- BIO-key® International, Inc. (NASDAQ: BKYI), a company that offers advanced identity and access management (IAM) solutions for secure authentication without the need for phones, tokens, or passwords, has announced that it is honored to have been featured in two Gartner reports over the last year.
MINNEAPOLIS, Nov. 27, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) has announced that Kim Kelderman, the President and CEO, will speak at the Citi 2024 Global Healthcare Conference on Wednesday, December 4, 2024, at 3:15 p.m. EST. You can watch the live webcast of the presentation on the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar.
BIO-key (BKYI) announced that its revenue for the third quarter of 2024 increased by 18% to $2.1 million. The company also reported a smaller net loss and a better cash position. They will hold a conference call tomorrow, Friday, November 15th, at 10 am ET.
R&D Systems Hematology Controls and Calibrators has successfully received Class B Certification under the new European Union In Vitro Diagnostic Regulation, changing its classification from Class C. This announcement was made by Bio-Techne Corporation (NASDAQ: TECH) on November 11, 2024, in Minneapolis. The certification confirms that their products meet the updated regulatory standards.
R&D Systems Hematology Controls and Calibrators has received Class C Certification under the new European Union In Vitro Diagnostic Regulation. Bio-Techne Corporation announced this achievement on November 11, 2024, confirming that their products meet the EU's standards for in-vitro diagnostic devices.
FAQ
- What is the primary business of Bio-Rad Laboratories?
- What is the ticker symbol for Bio-Rad Laboratories?
- Does Bio-Rad Laboratories pay dividends?
- What sector is Bio-Rad Laboratories in?
- What industry is Bio-Rad Laboratories in?
- What country is Bio-Rad Laboratories based in?
- When did Bio-Rad Laboratories go public?
- Is Bio-Rad Laboratories in the S&P 500?
- Is Bio-Rad Laboratories in the NASDAQ 100?
- Is Bio-Rad Laboratories in the Dow Jones?
- When was Bio-Rad Laboratories's last earnings report?
- When does Bio-Rad Laboratories report earnings?
- Should I buy Bio-Rad Laboratories stock now?